Oxaprozin

CHEMBL1071 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

293.3 g/mol

LogP

4.2

Phase

4

A long-acting NSAID allowing once-daily dosing for arthritis pain and inflammation.

Peso Molecular

293,3000 g/mol

LogP

4,20

TPSA

63,30 Å²

Regra dos 5 de Lipinski

Aprovado

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1

InChI

InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)

Molecular Formula

C18H15NO3

HBD / HBA

1 / 4

Ligações Rotacionáveis

5

Átomos Pesados

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A long-acting NSAID allowing once-daily dosing for arthritis pain and inflammation.

Yes, Oxaprozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1071. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4614. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Oxaprozin no PillFYI

Estrutura

Dados Rápidos

Fórmula: C18H15NO3
Sinônimos: 2

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.